Cyclerion Therapeutics Inc (CYCN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $33.72 (+7.97%), Market cap $0.01B, 52-week low–high $1.08 ~ $6.38.
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambrid
Financial statements, price targets, institutional (13F) holdings and related news for Cyclerion Therapeutics Inc are updated in real time on BlackAll Trade.
Cyclerion Therapeutics Inc trades at $33.72 (+7.97%). Real-time quotes and charts are available on BlackAll Trade.
Cyclerion Therapeutics Inc has a market cap of about $0.01B.
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system